Skip to main content
PGEN
NASDAQ Life Sciences

Precigen Posts $35.8M Q3 Profit as Papzimeos Revenue Hits $72.9M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$4.987
Mkt Cap
$1.81B
52W Low
$3.04
52W High
$8.98
52W Position info
64% above low
Off High info
44% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

PGEN sits 64% above its 52-week low of $3.04 on elevated volume (1.9× avg).

Summary

Precigen earned $35.8 million in Q3 2026 on $74.1 million of revenue, almost all from Papzimeos, but cash fell to $51.0 million as $96.5 million sat in receivables. Three executives also set up new 10b5-1 sales plans.


Key Events · Earnings and Guidance · PGEN

  • Q3 Profit on Papzimeos Sales

    Q3 2026 revenue was $74.1 million, including $72.9 million of Papzimeos product revenue, versus $2.9 million a year earlier. Net income was $35.8 million, or $0.10 per basic share.

  • Cash Tight Despite Profit

    Cash, cash equivalents and investments totaled $51.0 million at September 30, 2026, down from $100.4 million at December 31, 2025, as trade receivables reached $96.5 million on 127-day Papzimeos payment terms.

  • Operating Cash Flow Turns Positive

    Q3 2026 operating cash flow was positive $11.9 million, though the nine-month figure remained an outflow of $49.8 million.

  • Debt and Runway

    $100 million principal outstanding on the Pharmakon term loan at a 12.5% effective rate, with eight quarterly $12.5 million principal payments beginning December 31, 2028. Management says liquidity plus Papzimeos collections funds at least one year.


Analysis · PGEN · Life Sciences

A second consecutive profitable quarter confirms Papzimeos is a real commercial product, not a launch promise: Q3 revenue of $74.1 million against $35.5 million of operating expenses produced $38.7 million of operating income. The catch is cash. Only $51.0 million of cash and investments remained at quarter-end because $96.5 million sits in receivables from a single wholesaler on 127-day payment terms, so reported profit runs well ahead of collected cash. Management says existing liquidity plus Papzimeos collections funds at least a year, but the $100 million Pharmakon term loan (12.5% effective rate, principal payments starting December 2028) and a stock near $5 keep dilution risk alive if collections slip. Separately, the CFO, COO and CCO all adopted new 10b5-1 selling plans effective late December 2026, adding a scheduled supply of shares over the next year.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PGEN was trading at $4.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $3.04 to $8.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PGEN - Latest Insights

PGEN
Nov 04, 2026, 4:05 PM EST
Source: PR Newswire
Importance Score:
8
Price at Filing: $5.01
Real-time Price: $4.13 info
Change: -$0.8813 (-18%) info
Market Cap: $1.483B info
PGEN
Sep 21, 2026, 7:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $7.93
Real-time Price: $4.13 info
Change: -$3.80 (-48%) info
Market Cap: $1.483B info
PGEN
Aug 04, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $7.27
Real-time Price: $4.13 info
Change: -$3.14 (-43%) info
Market Cap: $1.483B info
PGEN
Aug 04, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.35
Real-time Price: $4.13 info
Change: -$3.22 (-44%) info
Market Cap: $1.483B info
PGEN
Aug 04, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.25
Real-time Price: $4.13 info
Change: -$3.12 (-43%) info
Market Cap: $1.483B info